Literature DB >> 18600286

Strontium ranelate-induced toxic epidermal necrolysis in a patient with post-menopausal osteoporosis.

H Y Lee1, D Lie, K S Lim, T Thirumoorthy, S M Pang.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18600286     DOI： 10.1007/s00198-008-0677-0

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN： 0937-941X            Impact factor:   4.507


× No keyword cloud information.
  4 in total

1.  Strontium ranelate for the treatment of osteoporosis.

Authors:  Ignac Fogelman; Glen M Blake
Journal:  BMJ       Date:  2005-06-18

2.  An estimate of the worldwide prevalence and disability associated with osteoporotic fractures.

Authors:  O Johnell; J A Kanis
Journal:  Osteoporos Int       Date:  2006-09-16       Impact factor: 4.507

Review 3.  Strontium ranelate for preventing and treating postmenopausal osteoporosis.

Authors:  S O'Donnell; A Cranney; G A Wells; J D Adachi; J Y Reginster
Journal:  Cochrane Database Syst Rev       Date:  2006-07-19

4.  The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis.

Authors:  Pierre J Meunier; Christian Roux; Ego Seeman; Sergio Ortolani; Janusz E Badurski; Tim D Spector; Jorge Cannata; Adam Balogh; Ernst-Martin Lemmel; Stig Pors-Nielsen; René Rizzoli; Harry K Genant; Jean-Yves Reginster
Journal:  N Engl J Med       Date:  2004-01-29       Impact factor: 91.245
  4 in total
  10 in total

1.  The 10th International Congress on Cutaneous Adverse Drug Reactions, Shimane, Japan, 2018: Focus on New Discoveries.

Authors:  Cristina Olteanu; Neil H Shear; Eishin Morita; Wen-Hung Chung; Hiroyuki Niihara; Setsuko Matsukura; Rena Hashimoto; Roni P Dodiuk-Gad
Journal:  Drug Saf       Date:  2019-06       Impact factor: 5.606

Review 2.  Screening, diagnosis and treatment of osteoporosis: a brief review.

Authors:  Roberto Bernabei; Anna Maria Martone; Elena Ortolani; Francesco Landi; Emanuele Marzetti
Journal:  Clin Cases Miner Bone Metab       Date:  2014-09

3.  Strontium fructose 1,6-diphosphate prevents bone loss in a rat model of postmenopausal osteoporosis via the OPG/RANKL/RANK pathway.

Authors:  Bo Ma; Qi Zhang; Di Wu; Yong-lu Wang; Ying-ying Hu; Yan-ping Cheng; Zhen-dong Yang; Ya-ya Zheng; Han-Jie Ying
Journal:  Acta Pharmacol Sin       Date:  2012-03-19       Impact factor: 6.150

4.  Cutaneous side effects of antiosteoporosis treatments.

Authors:  Philippe Musette; Jean-Marc Kaufman; René Rizzoli; Patrice Cacoub; Maria Louisa Brandi; Jean-Yves Reginster
Journal:  Ther Adv Musculoskelet Dis       Date:  2011-02       Impact factor: 5.346

Review 5.  Fever, rash, and systemic symptoms: understanding the role of virus and HLA in severe cutaneous drug allergy.

Authors:  Rebecca Pavlos; Simon Mallal; David Ostrov; Yuri Pompeu; Elizabeth Phillips
Journal:  J Allergy Clin Immunol Pract       Date:  2014 Jan-Feb

6.  Alopecia associated with strontium ranelate use in a 62-year-old woman.

Authors:  Y-Y Lee; C-H Yang; C-H Chen; J-S Hwang
Journal:  Osteoporos Int       Date:  2012-04-12       Impact factor: 4.507

7.  Increased risk of strontium ranelate-related SJS/TEN is associated with HLA.

Authors:  H Y Lee; M X Shen; Y L Lim; Y K Tay; M M F Chan; S M Pang; Z W Xiao; S B Ang; E C Ren
Journal:  Osteoporos Int       Date:  2016-03-22       Impact factor: 4.507

8.  Extraskeletal benefits and risks of calcium, vitamin D and anti-osteoporosis medications.

Authors:  J-J Body; P Bergmann; S Boonen; J-P Devogelaer; E Gielen; S Goemaere; J-M Kaufman; S Rozenberg; J-Y Reginster
Journal:  Osteoporos Int       Date:  2012-02-04       Impact factor: 4.507

9.  Strontium ranelate related Stevens-Johnson syndrome: a case report.

Authors:  C-Y Yang; C-H Chen; H-Y Wang; H-L Hsiao; Y-H Hsiao; W-H Chung
Journal:  Osteoporos Int       Date:  2014-04-01       Impact factor: 5.071

Review 10.  Treatment of osteoporosis: recognizing and managing cutaneous adverse reactions and drug-induced hypersensitivity.

Authors:  P Musette; M L Brandi; P Cacoub; J M Kaufman; R Rizzoli; J-Y Reginster
Journal:  Osteoporos Int       Date:  2009-11-17       Impact factor: 5.071
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.